ScholarLens Back to search
2000•Unpublished venueRequires access

Pharmacological Treatment of Obsessive‐Compulsive Disorder: A Review

Joseph Zohar, Yehuda Sasson, Miriam Chopra, Daniella Amital, Iulian Iancu

Open publisher page 7 citations

Abstract

The well-established finding that patients with obsessive-compulsive disorder (OCD) respond to a particular group of drugs – serotonin reuptake inhibitors (SRIs) – which have specific effect on the activity of the serotonergic neurotransmitter system, has changed the outlook for OCD sufferers. Since the early 1980s, several potent SRIs have been studied extensively in OCD. Aggregate statistics for all SRIs suggest that 70% of treatment-naïve patients will improve at least moderately. With the specific response of OCD patients to compounds with serotonin reuptake blocking activity, the understanding of the biochemical nature and origins of OCD begins to unfold.

About this research paper

What this paper is about

The well-established finding that patients with obsessive-compulsive disorder (OCD) respond to a particular group of drugs – serotonin reuptake inhibitors (SRIs) – which have specific effect on the activity of the serotonergic neurotransmitter system, has changed the outlook for OCD sufferers. Since the early 1980s, several potent SRIs have been studied extensively in OCD. Aggregate statistics for all SRIs suggest that 70% of treatment-naïve patients will improve at least moderately. With the specific response of OCD patients to compounds with serotonin reuptake blocking activity, the understanding of the biochemical nature and origins of OCD begins to unfold.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The well-established finding that patients with obsessive-compulsive disorder (OCD) respond to a particular group of drugs – serotonin reuptake inhibitors (SRIs) – which have specific effect on the activity of the serotonergic neurotransmitter system, has changed the outlook for OCD sufferers. Since the early 1980s, several potent SRIs have been studied extensively in OCD. Aggregate statistics for all SRIs suggest that 70% of treatment-naïve patients will improve at least moderately. With the specific response of OCD patients to compounds with serotonin reuptake blocking activity, the understanding of the biochemical nature and origins of OCD begins to unfold.

Key concepts: Serotonergic, Obsessive compulsive, Neurotransmitter systems, Reuptake inhibitor, Serotonin, Reuptake, Neurotransmitter, Psychology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Pharmacological Treatment of Obsessive‐Compulsive Disorder: A Review — Research Paper | ScholarLens